/
BCTX
$3.54+$0.03 (+0.88%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$29.7M
9M shares
52-week range
$2.60 – $14.68
8% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-790.06
Briacell Therapeutics Corp. Common Shares
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
www.briacell.com- Employees
- 4
- IPO / List date
- Sep 5, 2023
- HQ
- WEST VANCOUVER, A1
Held by traders on TradeandTell
No one on the platform currently holds BCTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in BCTX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-25 | 1-for-10reverse |
| 2025-01-29 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded BCTX yet.
